PFO
NBIX icon

Pathstone Family Office’s Neurocrine Biosciences NBIX Stock Holding History

Pathstone Family Office’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$323K Buy
+2,870
New +$302K ﹤0.01% 1266
2017
Q4 		– Sell
-250
Closed -$15K – 189
2017
Q3 		$15K Buy
+250
New +$13.2K 0.01% 114

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Family Office's NBIX Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Neurocrine Biosciences (NBIX) in Q3 2023: 2,870 shares worth $323K. The stake represents ﹤0.01% of the portfolio and ranks #1266 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in NBIX as recently as Q3 2017.

Pathstone Family Office first reported a position in NBIX in Q3 2017 and has held it in 2 quarters since. 512 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • Pathstone Family Office held 2,870 shares of Neurocrine Biosciences worth $323K as of Q3 2023.
  • Neurocrine Biosciences was a new Pathstone Family Office position in Q3 2023.
  • Neurocrine Biosciences made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1266 holding.
  • Pathstone Family Office first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 2 quarters since.
  • 512 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.